HOME > BUSINESS
BUSINESS
- Toray, Taiho Terminate Co-Development of β3-Adrenoceptor Agonist
April 2, 2012
- NanoCarrier Enters into Joint Research Agreement with Eisai for Its Drug Discovery Platform Technology
April 2, 2012
- Astellas Enters into Partnership with US Company to Develop, Market Fidaxomicin in Japan
April 2, 2012
- Novartis Files for Add’l Indication of DME for Lucentis
April 2, 2012
- Tempstaff, IUK to Form PV Management Joint Venture in May
March 30, 2012
- Astellas, Pfizer Extend Lipitor Licensing Term
March 30, 2012
- Daiichi Sankyo Enters Research Collaboration Agreement on Diabetes Therapy with US Venture Company
March 30, 2012
- Otsuka Chemical to Split Up Glycotechnology Laboratory to Make It New Company
March 30, 2012
- More Than 70% of Doctors Say “Frequency of Meetings Will Not Change” Despite Review of Entertainment: CareNet Survey
March 29, 2012
- Takeda’s Novel Renal Anemia Drug Omontys Approved in the US
March 29, 2012
- Astellas Files MAA for Fixed-Dose Combination of Vesicare/Harnal in Europe
March 29, 2012
- Fujifilm, Kyowa Hakko Kirin Establish JV to Develop Biosimilars
March 29, 2012
- No Change in Wholesalers’ Business Entertaining Rules for Time Being; Status of MSs with MR Qualification Remains Unclear
March 29, 2012
- Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
- Nippon Shinyaku Submits NDA for Alcohol Abstinence Aid Acamprosate
March 28, 2012
- Ajinomoto, Takeda Submit Domestic Application for Once-Monthly Risedronate
March 28, 2012
- Anticancer Agents Set to Become Top Therapeutic Category in 2012: IMS Japan
March 28, 2012
- Nichi-Iko Provides Wholesalers with Monthly Supply Volume of Epadel Generic
March 27, 2012
- Epadel Generic in Short Supply at Sawai Pharmaceutical Due to Promotional Measures
March 26, 2012
- Daiichi Sankyo Submits NDA for Denosumab for Osteoporosis in Japan
March 26, 2012
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…